Medical Research Council

NeoPhore , which launched in November 2017 with funding from Sixth Element Capital LLP, is developing first-in-class small molecules that stimulate the immune system to attack cancer; the UK-based com

Alcresta Inc. Alcresta brings in $49.4m via Series C Alcresta Inc. (therapies for gastrointestinal disorders and rare diseases) raised $49.4m in its Series C financing to new backer Athyrium a

Kymab Ltd. CEO Dr David Chiswell OBE has more than 30 years of experience in the biotechnology industry, having co-founded Cambridge Antibody Technology Group PLC in 1990, a company that origina

PHARMACEUTICALS AbbVie Inc. University of Chicago AbbVie , U. Chicago ally in cancer research In a five-year collaboration, AbbVie Inc. is teaming up with the University of Chicago in can